Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CNS CANCER

Immunotherapy for glioblastoma: quo vadis?

Nature Reviews Clinical Oncology volume 16, pages 405–406 (2019)Cite this article

Subjects

Glioblastoma remains essentially incurable, and new therapeutic approaches are urgently needed. Now, the findings of three serial tissue-based studies suggest that immune-checkpoint inhibition can modify the glioblastoma microenvironment. Following these encouraging observations, the results of two phase III trials of immune-checkpoint inhibition in newly diagnosed glioblastoma, with larger cohorts of patients, are eagerly anticipated.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 1, 15017 (2015).

    Article  Google Scholar 

  2. Weller, M. et al. EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315–e329 (2017).

    Article  Google Scholar 

  3. Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

    Article  CAS  Google Scholar 

  4. Reardon, D. A. et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab versus bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol. 19, iii21 (2017).

    Article  Google Scholar 

  5. Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).

    Article  CAS  Google Scholar 

  6. Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-019-0349-y (2019).

    Article  PubMed  Google Scholar 

  7. Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-018-0339-5 (2019).

    Article  PubMed  Google Scholar 

  8. Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. https://doi.org/10.1038/s41591-018-0337-7 (2019).

    Article  PubMed  Google Scholar 

  9. Weller, M. Where does O6-methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? Cancer 124, 1316–1318 (2018).

    Article  Google Scholar 

  10. Weiss, T. et al. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. Clin. Cancer Res. 24, 882–895 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

    Michael Weller

  2. CHU Lille, Neuro-oncology, General and Stereotaxic Neurosurgery Service, Lille, France

    Emilie Le Rhun

Authors
  1. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilie Le Rhun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Weller.

Ethics declarations

Competing interests

M.W. has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche and honoraria for lectures, participation in advisory boards and/or consultancy from Abbvie, Basilea, Bristol-Myers Squibb, Celgene, MSD, Merck (EMD), Novocure, Orbus, Roche and Tocagen. E.L.R. has received research grants Amgen, Mundipharma; honoraria for lectures or participation in advisory boards for Abbvie, Daiichi-Sankyo and Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weller, M., Le Rhun, E. Immunotherapy for glioblastoma: quo vadis?. Nat Rev Clin Oncol 16, 405–406 (2019). https://doi.org/10.1038/s41571-019-0195-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-019-0195-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer